Recent News
February 12th, 2013 - EpiCept Corporation and Immune Pharmaceuticals Amend Merger Agreement
January 9th, 2013 - Daniel Teper of Immune Pharmaceuticals to Present at the 6th Annual OneMedForum
November 14th, 2012 - EpiCept Reports Third Quarter 2012 Operating and Financial Results
November 12th, 2012 - EpiCept to Report Third Quarter 2012 Operating and Financial Results on November 14, 2012
November 8th, 2012 - Immune Pharmaceuticals and EpiCept Corporation Agree to Merge
October 19th, 2012 - EpiCept Corporation Receives One-Month Extension to Loan and Security Agreement
September 25th, 2012 - EpiCept Corporation Raises $0.8 Million from Immediate Exercise of Re-priced Warrants
August 30th, 2012 - EpiCept Announces Changes to Its Board of Directors
August 21st, 2012 - EpiCept Announces Resignation of CEO Jack Talley
August 8th, 2012 - EpiCept Reports Second Quarter 2012 Operating and Financial Results
August 2nd, 2012 - EpiCept to Report Second Quarter 2012 Operating and Financial Results on August 8, 2012
June 19th, 2012 - EpiCept Transfers Ceplene Responsibilities in European Union and Sells License Rights to Meda
June 12th, 2012 - EpiCept Corporation to Present at 2012 BIO International Convention
June 4th, 2012 - EpiCept Corporation Receives Scientific Advice from European Medicines Agency for AmiKet™ CIPN Program
May 9th, 2012 - EpiCept Reports First Quarter 2012 Operating and Financial Results
Pioneering Cancer Therapy and Pain Relief
EpiCept is a specialty pharmaceutical company seeking to address areas of high, unmet medical needs in cancer and pain through its innovative technologies. We are headquartered in Tarrytown, New York. EpiCept is listed on both the Nasdaq OMX Stockholm Exchange and the U.S. OTCQX under the symbol “EPCT”.